DYRK1A inhibitors for disease therapy: Current status and perspectives
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DYRK1A inhibitors for disease therapy: Current status and perspectives
Authors
Keywords
DS, Cancer, DYRK1A, DYRK1A inhibitor, Drug design, Structure activity relationships
Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 229, Issue -, Pages 114062
Publisher
Elsevier BV
Online
2021-12-21
DOI
10.1016/j.ejmech.2021.114062
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3
- (2021) Rahul S. Bhansali et al. JOURNAL OF CLINICAL INVESTIGATION
- Perspectives on the Role of Isoliquiritigenin in Cancer
- (2021) Kai-Lee Wang et al. Cancers
- DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes
- (2021) Kunal Kumar et al. JOURNAL OF MEDICINAL CHEMISTRY
- DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells
- (2021) Brianna Chen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors
- (2021) Csaba Weber et al. JOURNAL OF MEDICINAL CHEMISTRY
- DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma
- (2021) Charlotte Ellen Martin et al. EXPERIMENTAL CELL RESEARCH
- GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways
- (2021) Stefania Demuro et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B
- (2021) David Lee Walmsley et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors
- (2021) Scott H. Henderson et al. JOURNAL OF MEDICINAL CHEMISTRY
- A natural DYRK1A inhibitor as a potential stimulator for β‐cell proliferation in diabetes
- (2021) Mengzhu Zheng et al. Clinical and Translational Medicine
- Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease
- (2021) Wenwu Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects
- (2021) Yasmeen T. AlNajjar et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes
- (2021) Miri Choi et al. PHYTOMEDICINE
- Synthesis of Four Optical Isomers of Antiviral Agent NK0209 and Determination of Their Configurations and Activities against a Plant Virus
- (2020) Haiqi Wang et al. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
- Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor
- (2020) Kunal Kumar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133
- (2020) Yahu A. Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration
- (2020) Courtney Ackeifi et al. Science Translational Medicine
- Glycogen synthase kinase-3 signaling in Alzheimer's disease
- (2020) Elisabetta Lauretti et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
- (2020) Xin Li et al. Journal of Hematology & Oncology
- Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
- (2020) Przemysław Duda et al. Cells
- A Dual Inhibitor of DYRK1A and GSK3β for β‐Cell Proliferation: Aminopyrazine Derivative GNF4877
- (2020) Yahu A. Liu et al. ChemMedChem
- Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer
- (2020) Saleh A. Almatroodi et al. MOLECULES
- Mining Public Domain Data to Develop Selective DYRK1A Inhibitors
- (2020) Scott H. Henderson et al. ACS Medicinal Chemistry Letters
- DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis
- (2020) Amina Jamal Laham et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- The USP22 promotes the growth of cancer cells through the DYRK1A in pancreatic ductal adenocarcinoma
- (2020) Zhile Bai et al. GENE
- Pharmacological effects of harmine and its derivatives: a review
- (2020) Liang Zhang et al. ARCHIVES OF PHARMACAL RESEARCH
- The PROTAC technology in drug development
- (2019) Yutian Zou et al. CELL BIOCHEMISTRY AND FUNCTION
- New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis
- (2019) Helmi Tazarki et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Single and dual targeting of mutant EGFR with an allosteric inhibitor
- (2019) Ciric To et al. Cancer Discovery
- Natural products in licorice for the therapy of liver diseases: Progress and future opportunities
- (2019) Xiaojiaoyang Li et al. PHARMACOLOGICAL RESEARCH
- Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment
- (2019) Lin-wen Wu et al. OncoTargets and Therapy
- Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus
- (2019) Simone Granno et al. Scientific Reports
- Multi-target design strategies for the improved treatment of Alzheimer's disease
- (2019) Pengfei Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
- (2019) Yang‐ling Li et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome
- (2019) Adolfo Quiñones-Lombraña et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Dual-specificity tyrosine phosphorylation-regulated kinase 1A ameliorates insulin resistance in neurons by up-regulating IRS-1 expression
- (2019) Shijiao Tian et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- [b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors
- (2019) Christian Lechner et al. MOLECULES
- Construction of miRNA-target networks using microRNA profiles of CVB3-infected HeLa cells
- (2019) Hai Lan Yao et al. Scientific Reports
- A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer
- (2019) Ke Huang et al. Cell Metabolism
- Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A
- (2019) Chao Zhao et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer’s Disease
- (2019) Karol Dowjat et al. JOURNAL OF ALZHEIMERS DISEASE
- microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing
- (2019) Juliana C.S. Chaves et al. NEUROSCIENCE LETTERS
- LncRNA OIP5-AS1 regulates radioresistance by targeting DYRK1A through miR-369-3p in colorectal cancer cells
- (2018) Yanmei Zou et al. EUROPEAN JOURNAL OF CELL BIOLOGY
- Development of novel 2,4-bispyridyl thiophene–based compounds as highly potent and Selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives
- (2018) Sarah S. Darwish et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics
- (2018) Dnyandev B. Jarhad et al. JOURNAL OF MEDICINAL CHEMISTRY
- Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design
- (2018) Rosanna Meine et al. MOLECULES
- DYRK1A-haploinsufficiency in mice causes autistic-like features and febrile seizures
- (2018) Matthieu Raveau et al. NEUROBIOLOGY OF DISEASE
- Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene
- (2018) Susana García-Cerro et al. NEUROBIOLOGY OF DISEASE
- Alzheimer’s disease and gut microbiota modifications: The long way between preclinical studies and clinical evidence
- (2018) Cesare Mancuso et al. PHARMACOLOGICAL RESEARCH
- Design and synthesis of conformationally constraint Dyrk1A inhibitors by creating an intramolecular H-bond involving a benzothiazole core
- (2018) Mohamed Salah et al. MedChemComm
- DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives
- (2018) Fernanda Neumann et al. Scientific Reports
- DYRK1A Kinase Positively Regulates Angiogenic Responses in Endothelial Cells
- (2018) Esteban J. Rozen et al. Cell Reports
- Analogous β-Carboline Alkaloids Harmaline and Harmine Ameliorate Scopolamine-Induced Cognition Dysfunction by Attenuating Acetylcholinesterase Activity, Oxidative Stress, and Inflammation in Mice
- (2018) Shu-Ping Li et al. Frontiers in Pharmacology
- Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity
- (2018) Kunal Kumar et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Development of novel amide–derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification
- (2018) Sarah S. Darwish et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation
- (2018) Kunal Kumar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of Kinase Inhibitors via Metal-Catalyzed C–H Arylation of 8-Alkyl-thiazolo[5,4-f]-quinazolin-9-ones Designed by Fragment-Growing Studies
- (2018) Florence Couly et al. MOLECULES
- Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells
- (2018) Peng Wang et al. Cell Metabolism
- DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth
- (2018) Jeroni Luna et al. GUT
- Dyrk1A promotes the proliferation, migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis via down-regulating Spry2 and activating the ERK MAPK pathway
- (2018) Xiaofeng Guo et al. TISSUE & CELL
- Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor
- (2017) Lyamin Z. Bendjeddou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature
- (2017) Thu Lan Nguyen et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma
- (2017) Qingqing Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases
- (2017) Nadège Loaëc et al. Marine Drugs
- Chemical screening identifies the β-Carboline alkaloid harmine to be synergistically lethal with doxorubicin
- (2017) Reham Atteya et al. MECHANISMS OF AGEING AND DEVELOPMENT
- Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development
- (2017) T Dang et al. MOLECULAR PSYCHIATRY
- Harmine suppresses the proliferation and migration of human ovarian cancer cells through inhibiting ERK/CREB pathway
- (2017) Jun Gao et al. ONCOLOGY REPORTS
- Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice
- (2017) Akiko Nakano-Kobayashi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- LncRNA OIP5-AS1/cyrano suppresses GAK expression to control mitosis
- (2017) Jiyoung Kim et al. Oncotarget
- The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model
- (2016) Daniela Valenti et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives
- (2016) Wael Zeinyeh et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways
- (2016) Jongchan Kim et al. CANCER RESEARCH
- Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2
- (2016) Marica Mariano et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co–crystal structure
- (2016) Yannick J. Esvan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules
- (2016) Ulli Rothweiler et al. JOURNAL OF MEDICINAL CHEMISTRY
- Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model
- (2016) Irushi Abeysekera et al. MOLECULAR NUTRITION & FOOD RESEARCH
- Synthesis of Thiazolo[5,4-f]quinazolin-9(8H)-ones as Multi-Target Directed Ligands of Ser/Thr Kinases
- (2016) Damien Hédou et al. MOLECULES
- The GBA , DYRK1A and MS4A6A polymorphisms influence the age at onset of Chinese Parkinson patients
- (2016) Kuan Fan et al. NEUROSCIENCE LETTERS
- Pd-Catalyzed and Copper Assisted Regioselective Sequential C2 and C7 Arylation of Thiazolo[5,4-f]quinazolin-9(8H)-one with Aryl Halides
- (2016) Marine Harari et al. ORGANIC LETTERS
- Selective inhibition of the kinase DYRK1A by targeting its folding process
- (2016) Isao Kii et al. Nature Communications
- A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma
- (2016) Aneesha Radhakrishnan et al. Scientific Reports
- Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis
- (2015) So Masaki et al. BIOORGANIC & MEDICINAL CHEMISTRY
- DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model
- (2015) N. Kurabayashi et al. EMBO REPORTS
- 10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A
- (2015) Hannes Falke et al. JOURNAL OF MEDICINAL CHEMISTRY
- A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologiesin vitro
- (2015) Séverine Coutadeur et al. JOURNAL OF NEUROCHEMISTRY
- Treatment with harmine ameliorates functional impairment and neuronal death following traumatic brain injury
- (2015) ZEQI ZHONG et al. Molecular Medicine Reports
- The Role of Cdk5 in Alzheimer’s Disease
- (2015) Shu-Lei Liu et al. MOLECULAR NEUROBIOLOGY
- A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication
- (2015) Peng Wang et al. NATURE MEDICINE
- DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications
- (2015) Ramzi Abbassi et al. PHARMACOLOGY & THERAPEUTICS
- Inhibition of DYRK1A and GSK3B induces human β-cell proliferation
- (2015) Weijun Shen et al. Nature Communications
- The Down syndrome-related protein kinase DYRK1A phosphorylates p27Kip1and Cyclin D1 and induces cell cycle exit and neuronal differentiation
- (2014) Ulf Soppa et al. CELL CYCLE
- Human CDC2-Like Kinase 1 (CLK1): A Novel Target for Alzheimer’s Disease
- (2014) Princi Jain et al. CURRENT DRUG TARGETS
- Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted Pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors
- (2014) Oussama Dehbi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part II
- (2014) Alicia Foucourt et al. MOLECULES
- Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part I
- (2014) Alicia Foucourt et al. MOLECULES
- Design and Synthesis of a Library of Lead-Like 2,4-Bisheterocyclic Substituted Thiophenes as Selective Dyrk/Clk Inhibitors
- (2014) Christian Schmitt et al. PLoS One
- Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors
- (2013) Kevin Anderson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Development of DANDYs, New 3,5-Diaryl-7-azaindoles Demonstrating Potent DYRK1A Kinase Inhibitory Activity
- (2013) Stéphanie Gourdain et al. JOURNAL OF MEDICINAL CHEMISTRY
- Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans
- (2013) Rafael De la Torre et al. MOLECULAR NUTRITION & FOOD RESEARCH
- Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate Recognition
- (2013) Meera Soundararajan et al. STRUCTURE
- Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s?
- (2012) Breland Smith et al. ACS Chemical Neuroscience
- Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues : A novel DYRK1A inhibitor class
- (2012) Cleopatra Neagoie et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Function of alternative splicing
- (2012) Olga Kelemen et al. GENE
- Antioxidant and antimicrobial activities of aporphinoids and other alkaloids from the bark ofAnnona salzmanniiA. DC. (Annonaceae)
- (2012) Emmanoel Vilaça Costa et al. NATURAL PRODUCT RESEARCH
- Hydroxybenzothiazoles as New Nonsteroidal Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1)
- (2012) Alessandro Spadaro et al. PLoS One
- Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment
- (2012) Daniel I. Brierley et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Association analysis of GSK3B and MAPT polymorphisms with Alzheimer's disease in Han Chinese
- (2011) Na Zhang et al. BRAIN RESEARCH
- Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents
- (2011) Pamela Kassis et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis, Protein Kinase Inhibitory Potencies, and in Vitro Antiproliferative Activities of Meridianin Derivatives
- (2011) Francis Giraud et al. JOURNAL OF MEDICINAL CHEMISTRY
- Leucettines, a Class of Potent Inhibitors of cdc2-Like Kinases and Dual Specificity, Tyrosine Phosphorylation Regulated Kinases Derived from the Marine Sponge Leucettamine B: Modulation of Alternative Pre-RNA Splicing
- (2011) Mansour Debdab et al. JOURNAL OF MEDICINAL CHEMISTRY
- β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer's Disease-Related Sites
- (2011) Danielle Frost et al. PLoS One
- Dyrk1A Positively Stimulates ASK1-JNK Signaling Pathway during Apoptotic Cell Death
- (2011) Hyoung Kyoung Choi et al. Experimental Neurobiology
- Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A)
- (2010) Tatyana Adayev et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles
- (2010) Sergi Aranda et al. FASEB JOURNAL
- MNB/DYRK1A as a multiple regulator of neuronal development
- (2010) Francisco J. Tejedor et al. FEBS Journal
- The role of DYRK1A in neurodegenerative diseases
- (2010) Jerzy Wegiel et al. FEBS Journal
- Synergistic role of sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis
- (2010) Susie A. Lee et al. HEPATOLOGY
- DYRK1A and DYRK3 Promote Cell Survival through Phosphorylation and Activation of SIRT1
- (2010) Xiumei Guo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer’s disease
- (2010) Young Shin Ryu et al. JOURNAL OF NEUROCHEMISTRY
- Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas
- (2010) C Holgren et al. ONCOGENE
- Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A
- (2010) Yasushi Ogawa et al. Nature Communications
- Sprouty2-Mediated Inhibition of Fibroblast Growth Factor Signaling Is Modulated by the Protein Kinase DYRK1A
- (2008) S. Aranda et al. MOLECULAR AND CELLULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search